Partial Hepatectomy

Ogilvie, Heneage

doi:10.1136/bmj.2.4846.1136

Cited by 11 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As mentioned above, the techniques used in liver transections were described in reports and were widely used. From the finger fracture technique described by Lin [15] to the use of the blunt end of a hemostat by Ogilvie [36] and the use of the blunt edge of a scalpel by Quattlebaum, a common goal can be perceived. The identification of different tissues, parenchyma vs. vessel, via the means of blunt dissection.…”

Section: Tools For Resectionmentioning

confidence: 99%

Surgical Therapy of Hepatocellular Carcinoma: State of the Art Liver Resection

Davakis¹,

Vailas²,

Kozadinos³

et al. 2022

Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) represents the third most common cause of cancer-related death, showing incremental growth rates throughout the last decades. HCC requires multidisciplinary approach in a group of patients suffering from underlying chronic liver disease, usually in the setting of cirrhosis. The mainstay of treatment in resectable cases is surgery, with anatomic and non-anatomic liver resections widely implemented, as well as liver transplantation in well-selected individuals. Nowadays, there is a variety of liver parenchyma transection devices used by hepatobiliary surgeons in specialized centers, which has significantly improved postoperative outcomes in HCC patients. Therefore, hepatectomy is considered safe and feasible and should be the main therapeutic option for HCC patients, candidates for resection. Liver resection utilizing cavitron ultrasonic aspirator in combination with bipolar radiofrequency ablation is safe and effective for the treatment of HCC with favorable clinical and oncological outcomes.

show abstract

Section: Tools For Resectionmentioning

confidence: 99%

Surgical Therapy of Hepatocellular Carcinoma: State of the Art Liver Resection

Davakis¹,

Vailas²,

Kozadinos³

et al. 2022

Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach

View full text Add to dashboard Cite

show abstract

“…One must also remember that Keen used his thumbnail in 1882 [5]. Ogilvie [67] used the blunt end of a haemostat in 1951, and Quattlebaum [68] used the blunt end of a scalpel to define and delimit the subtle difference in resistance between the thin-walled blood vessels and liver parenchyma. Apparently unaware of Quattlebaum's report and thinking that he would be the first to do a socalled right hepatic lobectomy in USA, George T Pack [69] performed the operation on a 40-year-old woman in 1952, 14 months after Lortat-Jacob and 10 months after Quattlebaum.…”

Section: Technical Tools For Liver Transectionmentioning

confidence: 99%

The history of liver surgery, hepatectomy and haemostasis

2010

View full text Add to dashboard Cite

Liver surgery has advanced remarkably, but major challenges remain. These include developing more efficient minimally invasive surgical techniques, improving patient selection for any given treatment modality, and eliminating the risk of recurrence, particularly in the liver. The use of techniques involving virtual reality and robotic surgery is developing. More accurate methods of determining liver functional reserve and investigating liver regeneration are necessary. The application of gene therapy to the management of liver tumours is in its infancy. Finally, in the area of liver transplantation, a solution to tissue tolerance is close and the possibility of xenografts is on the horizon.

show abstract

“…Palliation had been the centerpiece of treatment in patients diagnosed with hepatic colorectal metastases. This was due both to the presumptive high risk of complex hepatic resection as well as to the mistaken belief that all patients with hematogenous metastases had widely distributed metastases in multiple organs (95). Data over the last three decades, however, have demonstrated that metastatic disease may be isolated to the liver and that a significant portion of the approximately 50,000 cases of hepatic colorectal metastases (116) encountered yearly in this country may be surgically curable.…”

Section: Introductionmentioning

confidence: 99%

Current Surgical Therapy of Hepatic Colorectal Metastasis

Stanziale

Fong

2002

European Surg

View full text Add to dashboard Cite

Summary: Background: Liver resection represents the only cure for patients with hepatic metastases from colorectal cancers. Methods: The discussion will address which patients should be considered for hepatic resection, what are the appropriate diagnostic modalities to employ, and what are the hallmarks of surgical therapy. The biologic determinants of recurrence as the basis for rational patient selection for hepatectomy will be addressed. This review will then concentrate on recent data guiding adjuvant therapy, and emerging developments for staging. Results: Median survival of patients after liver resection for hepatic metastases is on the order of 40 months (45, 93, 105), five‐year survival is 30 % – 40 %, and ten‐year survival approximately 20 %. Operative mortality at most major centers is uniformly less than 5 %. Conclusions: These comparative results have made any random‐assignment trial of resection versus nonresectional approach unethical and resection the standard of care.

show abstract

Partial Hepatectomy

Cited by 11 publications

References 2 publications

Surgical Therapy of Hepatocellular Carcinoma: State of the Art Liver Resection

Surgical Therapy of Hepatocellular Carcinoma: State of the Art Liver Resection

The history of liver surgery, hepatectomy and haemostasis

Current Surgical Therapy of Hepatic Colorectal Metastasis

Contact Info

Product

Resources

About